# Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)

> **NCT00613106** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 179 (actual)

## Conditions studied

- Osteoarthritis
- Rheumatoid Arthritis
- Chronic Low Back Pain
- Chronic Regional Pain Syndrome
- Chronic Soft Tissue Pain

## Interventions

- **DRUG:** HZT-501
- **DRUG:** Ibuprofen

## Key facts

- **NCT ID:** NCT00613106
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00613106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00613106, "Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00613106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*